Plasma infliximab monitoring contributes to optimize Takayasu arteritis treatment: a case report.

Sho MasuiAtsushi YonezawaKazushi IzawaMakoto HayakariKayoko AsakuraRisa TaniguchiMasahiko IsaHirofumi ShibataTakahiro YasumiRyuta NishikomoriJunko TakitaKazuo Matsubara

Published in: Journal of pharmaceutical health care and sciences (2019)

Monitoring of plasma IFX levels can be a potential tool to optimize the treatment in Takayasu arteritis patients.

Keyphrases

end stage renal disease
newly diagnosed
climate change